Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs

被引:80
|
作者
Abadji, V [1 ]
Lucas-Lenard, JM [1 ]
Chin, CN [1 ]
Kendall, DA [1 ]
机构
[1] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA
关键词
adenylyl cyclase; cannabinoid receptor; G protein-coupled receptor; cyclic AMP; G(s); G(j);
D O I
10.1046/j.1471-4159.1999.0722032.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human cannabinoid receptor CB1 functionally couples primarily to G(i)-, but also to G(s)-mediated pathways to modulate intracellular cyclic AMP (cAMP) levels. To probe the features of the receptor that may be involved in promoting interactions with one G protein type over another, we generated the L341A/A342L mutant CB1 receptor. The double mutation involved the swap in position of two adjacent residues in the carboxyl-terminal segment of the third intracellular loop of CB1, This resulted in partial constitutive activation of the receptor and an agonist-independent enhancement in cAMP levels. Characterization following treatment with either pertussis or cholera toxin indicated that the constitutive activity is selective for a G(s)- and not a G(i)-mediated pathway, Treatment with the CB1-specific inverse agonist SR141716A inhibited the basal accumulation of cAMP in the presence of pertussis toxin, establishing that the effect is CB1 mediated. The binding of the agonist CP-55,940 to the L341A/A342L receptor was not markedly different from that for the wild-type receptor despite the constitutive G(s) activity. This may reflect a preference of this ligand for an activated receptor state associated with the G(i) coupling form and underscores the potential for developing therapeutics that selectively activate one pathway over another.
引用
收藏
页码:2032 / 2038
页数:7
相关论文
共 50 条
  • [41] The cannabinoid CB1 receptor is expressed in pancreatic δ-cells
    Tharp, William G.
    Lee, Yong-Ho
    Maple, Rhonda L.
    Pratley, Richard E.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (04) : 595 - 600
  • [42] Recent advances in CB1 cannabinoid receptor antagonists
    Lange, JHM
    Kruse, CG
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (04) : 498 - 506
  • [43] Transmembrane Helical Domain of the Cannabinoid CB1 Receptor
    Shim, Joong-Youn
    BIOPHYSICAL JOURNAL, 2009, 96 (08) : 3251 - 3262
  • [44] Receptor dimerization of the μ-opioid and cannabinoid CB1 receptors
    Uezono, Y
    Matsumoto, M
    Kanaide, M
    Hojo, M
    Sumikawa, K
    Taniyama, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 134P - 134P
  • [45] Changes in the density of the cannabinoid CB1 receptor in schizophrenia
    Sundram, S
    Bradbury, R
    Scarr, E
    Copolov, DL
    Dean, B
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 85 - 85
  • [46] Pharmacophoric mapping of the CB1 cannabinoid receptor.
    Tong, WD
    Collantes, ER
    Shim, JY
    Welsh, WJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 12 - COMP
  • [47] Intracellular Cannabinoid Type 1 (CB1) Receptors Are Activated by Anandamide
    Brailoiu, G. Cristina
    Oprea, Tudor I.
    Zhao, Pingwei
    Abood, Mary E.
    Brailoiu, Eugen
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (33) : 29166 - 29174
  • [48] Pentacycle derivatives as cannabinoid CB1 receptor ligands
    Lee, Suk Ho
    Seo, Hee Jeong
    Kim, Min Ju
    Kang, Suk Youn
    Lee, Sung-Han
    Ahn, Kwangwoo
    Lee, MinWoo
    Han, Ho-Kyun
    Kim, Jeongmin
    Lee, Jinhwa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6632 - 6636
  • [49] CB1 Cannabinoid Receptor Signaling and Biased Signaling
    Leo, Luciana M.
    Abood, Mary E.
    MOLECULES, 2021, 26 (17):
  • [50] Substituted pyrimidines as cannabinoid CB1 receptor ligands
    Kim, Min Ju
    Kim, Jong Yup
    Seo, Hee Jeong
    Lee, Junwon
    Lee, Sung-Han
    Kim, Mi-Soon
    Kang, Jahyo
    Kim, Jeongmin
    Lee, Jinhwa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4692 - 4697